Clinical and imaging correlations of bone turnover markers in prostate cancer patients with bone only metastases

Nuclear Medicine Communications

Volumn 31, Issue 3, 2010, Pages 249-253

  Zafeirakis, Athanasios G ^a   Papatheodorou, Georgios A ^b   Limouris, Georgios S ^c  

^a 401 GENERAL MILITARY HOSPITAL OF ATHENS   (Greece)

^b 401 Army Hospital of Athens   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

Bone metastases; Bone turnover markers; Prostate cancer

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE PAIN; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; KARNOFSKY PERFORMANCE STATUS; MALE; PAIN ASSESSMENT; PROSTATE CANCER; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BONE AND BONES; BONE NEOPLASMS; CASE-CONTROL STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; OSTEOCALCIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 76749084766     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328335a5ed     Document Type: Article

References (32)

1. Jacobs SC. Spread of prostatic cancer to bone. Urology 1983; 21:337-344.
2. Jemal A, Siegel R,Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96.
3. Fohr B, Dunstan CR, Seibel MJ. Markers of bone remodeling in metastatic bone disease. J Clin Endocrinol Metab 2003; 88:5059-5075.
4. Vinholes J, Coleman R, Eastell R. Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat Rev 1996; 22:289-331.
5. Koopmans N, De Jong IJ, Breeuwsma AJ, Van Der Veer E. Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach. J Urol 2007; 178:849-853.
6. Coleman RE. The clinical use of bone resorption markers in patients with malignant bone disease. Cancer 2002; 94:2521-2533.
7. Michaelson MD, Marujo RM, Smith MR. Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer. Clin Cancer Res 2004; 10:2705-2708.
8. Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Clin Orthop 2003; 415:S138-S147.
9. Seibel MJ. The use of molecular markers of bone turnover in the management of patients with metastatic bone disease. Clin Endocrinol (Oxf) 2008; 68:839-849.
10. Imbriaco M, Larson SM, Yeung HW, Mawlawi OR, Erdi Y, Venkatraman ES, Scher HI. A new parameter for measuring metastatic bone involvement by prostate cancer: the bone scan index. Clin Cancer Res 1998; 4:1765-1772.
11. Fang N, Li Y, Xu YS, Ma D, Fu P, Gao HQ, et al., Serum concentrations of IL-2 and TNF-a in patients with painful bone metastases: correlation with responses to 89SrCl2 therapy. J Nucl Med 2006; 47:242-246.
12. Karnofsky DA, Abelmann WH, Craver LF. The use of nitrogen mustards in the palliative treatment of cancer. Cancer 1948; 1:634-656.
13. Hoskin PJ, Stratford MR, Folkes LK, Regan J, Yarnold JR. Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity. Lancet 2000; 355:1428-1429.
14. Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, et al., Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008; 113:193-201.
15. Arai Y, Takeuchi H, Oishi K, Yoshida O. Osteocalcin: is it a useful marker of bone metastasis and response to treatment in advanced prostate cancer? Prostate 1992; 20:169-177.
16. Plebani M, Bernardi D, Zaninotto M, De Paoli M, Secchiero S, Sciacovelli L. New and traditional serum markers of bone metabolism in the detection of skeletal metastases. Clin Biochem 1996; 29:67-72.
17. Lorente JA, Valenzuela H, Morote J, Gelabert A. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients. Eur J Nucl Med 1999; 26:625-632.
18. Schoenberger J, Rozeboom S, Wirthgen-Beyer E, Eilles C. Evaluation of the clinical value of bone metabolic parameters for the screening of osseous metastases compared to bone scintigraphy. BMC Nucl Med 2004; 4:1-9.
19. Hegele A, Wahl HG, Varga Z, Sevinc S, Koliva L, Schrader AJ, et al., Biochemical markers of bone turnover in patients with localized and metastasized prostate cancer. BJU Int 2007; 99:330-334.
20. Wolff JM, Ittel TH, Borchers H, Boekels O, Jakse G. Metastatic workup of patients with prostate cancer employing alkaline phosphatase and skeletal alkaline phosphatase. Anticancer Res 1999; 19:2653-2655.
21. Francini G, Gonnelli S, Petrioli R, Bruni S, Marsili S, Aquino A, Camporeale A. Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases. Cancer Epidemiol Biomarkers Prev 1993; 12:125-129.
22. Koizumi M, Yonese J, Fukui I, Ogata E. The serum level of the aminoterminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int 2001; 87:348-351.
23. Costa L, Demers LM, Gouveia-Oliveira A, Schaller J, Costa EB, De Moura MC, Lipton A. Prospective evaluation of the peptide-bound collagen Type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 2002; 20:850-856.
24. Lein M, Miller K, Wirth M, Weissbach L, May C, Schmidt K, et al., Complications in men with metastatic prostate cancer treated with zoledronic acid. Prostate 2009; 69:624-632.
25. Percival RC, Urwin GH, Harris S, Yates AJ, Williams JL, Beneton M, Kanis JA. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol 1987; 13:41-49.
26. Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer 2000; 88:2919-2926.
27. Akimoto S, Furuya Y, Akakura K, Shimazaki J, Ito H. Inability of bone turnover marker as strong prognostic indicator in prostate cancer patients with bone metastasis: comparison with the extent of disease (EOD) grade. The Prostate 1999; 38:28-34.
28. Berruti A, Dogliotti L, Gorzegno G, Torta M, Tampellini M, Tucci M, et al., Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem 1999; 45:1240-1247.
29. Leeming DJ, Koizumi M, Byrjalsen I, Li B, Qvist P, Tankó LB. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev 2006; 15:32-38.
30. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, et al., Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23:4925-4935.
31. Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTX): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 2002; 31:57-66.
32. Seibel MJ, Lang M, GeilenkeuserWJ. Interlaboratory variation of biochemical markers of bone turnover. Clin Chem 2001; 47:1443-1450.